The Medicines and Healthcare products Regulatory Agency (MHRA) consultation on the future role and remit of the agency, as the UK moves out of the standstill period and into mandatory UKCA marking for medtech and health products, goes beyond regulatory processes alone by also canvassing views on preferred new mechanisms for championing innovation.
The agency is keen to set up systems to ensure that targeted innovation rapidly enters into circulation in the UK. Some of the MHRA’s current thinking was revealed at the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?